64  -43.85 (-40.66%)		07-26 16:00
Open: 66 High: 67.44 Volume: 53,667,927		Pre. Close: 107.85 Low: 62.34 Market Cap: 25,452(M)

Short term
Mid term
Targets	6-month :	112.46	1-year :	136.97
Resists	First :	96.28	Second :	117.26
Pivot price	108.86
Supports	First :	62.34	Second :	51.86
MAs	MA(5) :	101.51	MA(20) :	109.77
	MA(100) :	124.57	MA(250) :	115.02
MACD	MACD :	-5.4	Signal :	-2.5
%K %D	K(14,3) :	12.8	D(3) :	22.7
RSI	RSI(14): 11.6
52-week	High :	142	Low :	62.34

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ DXCM ] has closed below the lower bollinger band by 42.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 234% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	67.51 - 68.06	68.06 - 68.43
Low:	61.26 - 61.83	61.83 - 62.22
Close:	63.23 - 64.14	64.14 - 64.75

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Fri, 26 Jul 2024
DXCM INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into DexCom, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Business Wire

Fri, 26 Jul 2024
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against DexCom, Inc. (DXCM) - Business Wire

Fri, 26 Jul 2024
The Law Offices of Frank R. Cruz Announces Investigation of DexCom, Inc. (DXCM) on Behalf of Investors - Business Wire

Fri, 26 Jul 2024
DexCom stock plummets on revenue miss. Are GLP-1s a headwind? - Yahoo Finance

Fri, 26 Jul 2024
DXCM INVESTIGATION ALERT: BFA Law Announces that it is - GlobeNewswire

Fri, 26 Jul 2024
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)? - Simply Wall St

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	398 (M)
Shares Float	394 (M)
Held by Insiders	0.3 (%)
Held by Institutions	97.4 (%)
Shares Short	10,310 (K)
Shares Short P.Month	8,740 (K)

EPS	1.53
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.67
Profit Margin	16.8 %
Operating Margin	10.9 %
Return on Assets (ttm)	6.7 %
Return on Equity (ttm)	28.5 %
Qtrly Rev. Growth	24.2 %
Gross Profit (p.s.)	0
Sales Per Share	9.55
EBITDA (p.s.)	2.13
Qtrly Earnings Growth	198.6 %
Operating Cash Flow	802 (M)
Levered Free Cash Flow	524 (M)

PE Ratio	41.55
PEG Ratio	3.5
Price to Book value	11.28
Price to Sales	6.69
Price to Cash Flow	31.72

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.